Walkiewicz K, Nowakowska-Zajdel E, Strzelczyk J, Dzięgielewska-Gęsiak S, Muc-Wierzgoń M
Department of Internal Medicine, School of Public Health in Bytom, Medical University of Silesia, Katowice, Poland.
Department of Nutrition Related Disease Prevention, School of Public Health in Bytom, Medical University of Silesia, Katowice, Poland.
J Biol Regul Homeost Agents. 2017 Oct-Dec;31(4):929-934.
Colorectal cancer is the third most common cancer in the world. Our study analyzed the potential significance of serum levels of selected adamalysines (ADAM10, ADAM12, ADAM17, ADAM28) in colorectal cancer patients. The study was performed on a group of 85 colorectal cancer patients (48 men, 37 women). Serum protein concentrations were measured by ELISA. The ADAMs serum level changes were analyzed according to selected clinical parameters (BMI, sex, age, clinical stage of disease). The following ranges of concentration of analyzed proteins were obtained: ADAM10 min=1.7, max=321.8 [ng/ml]; ADAM12 min=0.6, max=26.7 [ng/ml]; ADAM17 min=0.4, max=9.8 [ng/ml]; ADAM28 min=17.1, max=1545.8 [ng/ml]. In addition, it was stated that there is a relationship between the serum level of ADAM28 and the degree of the clinical stage (p less than 0.04). The obtained results could be the starting point for further research into the role of adamalysines in the development of colorectal cancer, as well as the potential predictive and prognostic value of these proteins.
结直肠癌是全球第三大常见癌症。我们的研究分析了血清中特定解聚素金属蛋白酶（ADAM10、ADAM12、ADAM17、ADAM28）水平在结直肠癌患者中的潜在意义。该研究对一组85例结直肠癌患者（48例男性，37例女性）进行。采用酶联免疫吸附测定法（ELISA）测量血清蛋白浓度。根据选定的临床参数（体重指数、性别、年龄、疾病临床分期）分析ADAMs血清水平变化。获得了以下分析蛋白的浓度范围：ADAM10最小值=1.7，最大值=321.8[纳克/毫升]；ADAM12最小值=0.6，最大值=26.7[纳克/毫升]；ADAM17最小值=0.4，最大值=9.8[纳克/毫升]；ADAM28最小值=17.1，最大值=1545.8[纳克/毫升]。此外，研究表明ADAM28血清水平与临床分期程度之间存在关联（P小于0.04）。所得结果可能是进一步研究解聚素金属蛋白酶在结直肠癌发生发展中的作用以及这些蛋白潜在的预测和预后价值的起点。
Zotero 插件